Clinical trials: Lupus Erythematosus, Discoid
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE).
- Trial name
- AMETHYST (NCT05531565)
- Testing
- Litifilimab
- Where
- 315 sites in United States, Argentina and 28 more
- Volunteers
- 450 people
- Sponsor
- Biogen
Discoid Lupus Erythematosus
Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions
Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin.
- Trial name
- NCT00625521
- Testing
- ASF 1096 0.5 % cream applied twice daily, Cream vehicle for ASF 1096 cream applied twice daily
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Astion Pharma A/S
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]
The purpose of this study is to evaluate the long-term safety and efficacy of orally administered enpatoran in participants with cutaneous manifestations of lupus erythematosus who have completed the Elowen-1 (MS504908_0001)…
- Trial name
- NCT07840287
- Testing
- Enpatoran
- Where
- 2 sites in United States, Germany
- Volunteers
- 404 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Cutaneous Lupus Erythematosus
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
This is the first study in cutaneous lupus erythematosus subjects to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CC-11050.
- Trial name
- NCT01300208
- Testing
- CC-11050
- Where
- 19 sites in United States
- Volunteers
- 48 people
- Sponsor
- Amgen
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
The purpose of this study is to obtain skin, blood, and urine samples from patients with active cutaneous lupus lesions and from healthy participants.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Healthy
- Trial name
- NCT02034344
- Testing
- Skin biopsy, Blood collection, Urine collection
- Where
- 21 sites in United States, Germany and 4 more
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Discoid Lupus Erythematosus
Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2)
Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin.
- Trial name
- NCT00625157
- Testing
- ASF 1096 0.5 % cream
- Where
- Denmark
- Sponsor
- Astion Pharma A/S
Lupus Erythematosus, Discoid
Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus
forty DLE lesions from patients will be recruited in the study. The lesions on one side of the body were block-randomized into the treatment group and the other side served as a control.
- Trial name
- NCT03178188
- Testing
- Pulsed-dye Laser
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- NCT07355218
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 57 sites in United States, Australia and 15 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Systemic Lupus Erythematosus
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus…
- Trial name
- NCT05540327
- Testing
- M5049 low dose, M5049 medium dose, M5049 high dose
- Where
- 122 sites in United States, Argentina and 20 more
- Volunteers
- 381 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.
- Trial name
- SKINDLE (NCT01597050)
- Testing
- R932333
- Where
- 15 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Rigel Pharmaceuticals
Lupus Erythematosus, Discoid
A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients with Higher Disease Activity (anti-dsDNA positive and low complement): A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and…
- Trial name
- NCT01858792
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Volunteers
- 1 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus…
- Trial name
- NCT05162586
- Testing
- Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 456 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE).
- Trial name
- NCT04857034
- Testing
- Deucravacitinib
- Where
- 41 sites in United States, Argentina and 6 more
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Discoid Lupus Erythematosus
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.
- Trial name
- NCT00708916
- Testing
- CC-10004
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
Discoid Lupus Erythematosus
Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)
- Trial name
- NCT04908280
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Rochester
Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)
Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE.
- Trial name
- NCT03159936
- Testing
- Tofacitinib citrate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tufts Medical Center
Cutaneous Lupus Erythematosus (CLE)
A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus
The research study is being conducted to learn more about how patients with cutaneous lupus erythematosus (CLE) respond to the use of quinacrine.
- Trial name
- NCT07694336
- Testing
- Quinacrine Hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Victoria Werth
Cutaneous Lupus, Discoid Lupus
Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
This is a multi-center, randomized, double-blind, placebo-controlled, two-period, crossover study in which approximately 20 subjects with Discoid Lupus Erythematosus will be enrolled to receive AMG 811 and placebo in one of two…
- Conditions
- Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
- Trial name
- NCT01164917
- Testing
- AMG811
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Amgen
Discoid Lupus Erythematosus
Topical Nicotinamide in Treatment of DLE
Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. In this autoimmune disease, the body's immune system attacks healthy skin.
- Trial name
- NCT05362188
- Testing
- Nicotinamide Topical
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Discoid Lupus Erythematosus
Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus
Discoid lupus erythematosus lesions are commonly treated with corticosteroids, but corticosteroids may induce side effects such as thinning of the skin or scarring.
- Trial name
- NCT00608673
- Testing
- Pimecrolimus 1% cream, betamethasone valerate 0.1% cream
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Shahid Beheshti University of Medical Sciences